PMID- 37525235 OWN - NLM STAT- MEDLINE DCOM- 20230802 LR - 20230803 IS - 2046-4053 (Electronic) IS - 2046-4053 (Linking) VI - 12 IP - 1 DP - 2023 Jul 31 TI - Clinical utility of overviews on adverse events of pharmacological interventions. PG - 131 LID - 10.1186/s13643-023-02289-z [doi] LID - 131 AB - BACKGROUND: Overviews (i.e., systematic reviews of systematic reviews, meta-reviews, umbrella reviews) are a relatively new type of evidence synthesis. Among others, one reason to conduct an overview is to investigate adverse events (AEs) associated with a healthcare intervention. Overviews aim to provide easily accessible information for healthcare decision-makers including clinicians. We aimed to evaluate the clinical utility of overviews investigating AEs. METHODS: We used a sample of 27 overviews exclusively investigating drug-related adverse events published until 2021 identified in a prior project. We defined clinical utility as the extent to which overviews are perceived to be useful in clinical practice. Each included overview was assigned to one of seven pharmacological experts with expertise on the topic of the overview. The clinical utility and value of these overviews were determined using a self-developed assessment tool. This included four open-ended questions and a ranking of three clinical utility statements completed by clinicians. We calculated frequencies for the ranked clinical utility statements and coded the answers to the open-ended questions using an inductive approach. RESULTS: The overall agreement with the provided statements was high. According to the assessments, 67% of the included overviews generated new knowledge. In 93% of the assessments, the overviews were found to add value to the existing literature. The overviews were rated as more useful than the individual included systematic reviews (SRs) in 85% of the assessments. The answers to the open-ended questions revealed two key aspects of clinical utility in the included overviews. Firstly, it was considered useful that they provide a summary of available evidence (e.g., along with additional assessments, or across different populations, or in different settings that have not been evaluated together in the included SRs). Secondly, it was found useful if overviews conducted a new meta-analysis to answer specific research questions that had not been answered previously. CONCLUSIONS: Overviews on drug-related AEs are considered valuable for clinical practice by clinicians. They can make available evidence on AEs more accessible and provide a comprehensive view of available evidence. As the role of overviews evolves, investigations such as this can identify areas of value. CI - (c) 2023. The Author(s). FAU - Sachse, Thilo AU - Sachse T AUID- ORCID: 0000-0001-9625-9858 AD - Faculty of Health, School of Medicine, Institute for Research in Operative Medicine, Witten/Herdecke University, 51109, Cologne, Germany. thilo.sachse@uni-wh.de. FAU - Kanji, Salmaan AU - Kanji S AD - The Ottawa Hospital and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. FAU - Thabet, Pierre AU - Thabet P AD - Hopital Montfort and University of Ottawa, Ottawa, Ontario, Canada. FAU - Schmiedl, Sven AU - Schmiedl S AD - Philipp Klee-Institute of Clinical Pharmacology, Helios University Hospital Wuppertal, Witten/Herdecke University, Chair of Clinical Pharmacology, Wuppertal, Germany. FAU - Thurmann, Petra AU - Thurmann P AD - Philipp Klee-Institute of Clinical Pharmacology, Helios University Hospital Wuppertal, Witten/Herdecke University, Chair of Clinical Pharmacology, Wuppertal, Germany. FAU - Guirguis, Fadi AU - Guirguis F AD - The Ottawa Hospital, Ottawa, Ontario, Canada. FAU - Sajwani, Shellyza AU - Sajwani S AD - The Ottawa Hospital, Ottawa, Ontario, Canada. FAU - Gauthier, Marie-France AU - Gauthier MF AD - Hopital Montfort and University of Ottawa, Ottawa, Ontario, Canada. FAU - Lunny, Carole AU - Lunny C AD - Knowledge Translation Program, Unity Health Toronto and the Cochrane Hypertension Group, St. Michael's Hospital, University of British Columbia, Vancouver, Canada. FAU - Mathes, Tim AU - Mathes T AD - Faculty of Health, School of Medicine, Institute for Research in Operative Medicine, Witten/Herdecke University, 51109, Cologne, Germany. AD - Institute for Medical Statistics, University Medical Center Gottingen, Gottingen, Germany. FAU - Pieper, Dawid AU - Pieper D AD - Faculty of Health, School of Medicine, Institute for Research in Operative Medicine, Witten/Herdecke University, 51109, Cologne, Germany. AD - Faculty of Health Sciences Brandenburg, Brandenburg Medical School (Theodor Fontane), Institute for Health Services and Health System Research, Rudersdorf, Germany. AD - Center for Health Services Research, Brandenburg Medical School (Theodor Fontane), Rudersdorf, Germany. LA - eng GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20230731 PL - England TA - Syst Rev JT - Systematic reviews JID - 101580575 SB - IM MH - Humans MH - *Delivery of Health Care MH - Health Facilities MH - *Publications MH - Systematic Reviews as Topic PMC - PMC10388527 OTO - NOTNLM OT - Adverse events OT - Clinical utility OT - Evidence synthesis OT - Meta-reviews OT - Overviews OT - Pharmacology COIS- The authors declare that they have no competing interests. EDAT- 2023/08/01 01:08 MHDA- 2023/08/02 06:42 PMCR- 2023/07/31 CRDT- 2023/07/31 23:45 PHST- 2022/09/12 00:00 [received] PHST- 2023/07/14 00:00 [accepted] PHST- 2023/08/02 06:42 [medline] PHST- 2023/08/01 01:08 [pubmed] PHST- 2023/07/31 23:45 [entrez] PHST- 2023/07/31 00:00 [pmc-release] AID - 10.1186/s13643-023-02289-z [pii] AID - 2289 [pii] AID - 10.1186/s13643-023-02289-z [doi] PST - epublish SO - Syst Rev. 2023 Jul 31;12(1):131. doi: 10.1186/s13643-023-02289-z.